XML 89 R28.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Fair Value Measurements - Assets and Liabilities at Fair Value (Details) - USD ($) $ in Thousands | Jun. 30, 2018 | Dec. 31, 2017
--- | --- | ---
Assets: |  |
Assets, fair value | $ 877,560 | $ 188,764
Liabilities: |  |
Liabilities, fair value | 11,800 | 13,961
Current portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 3,618 | 4,618
Current contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 36 | 86
Long-term portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 3,784 | 3,783
Long-term contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 1,503 | 1,503
Long-term contingent liabilities-Metabasis |  |
Liabilities: |  |
Liabilities, fair value | 2,859 | 3,971
Short-term investments |  |
Assets: |  |
Assets, fair value | 865,264 | 181,041
Note Receivable - Viking Therapeutics |  |
Assets: |  |
Assets, fair value | 0 | 3,877
Investment in Warrants |  |
Assets: |  |
Assets, fair value | 12,296 | 3,846
Quoted Prices in Active Markets for Identical Assets (Level 1) |  |
Assets: |  |
Assets, fair value | 73,689 | 5,742
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-Metabasis |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments |  |
Assets: |  |
Assets, fair value | 61,393 | 1,896
Quoted Prices in Active Markets for Identical Assets (Level 1) | Note Receivable - Viking Therapeutics |  |
Assets: |  |
Assets, fair value | 0 | 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in Warrants |  |
Assets: |  |
Assets, fair value | 12,296 | 3,846
Significant Other Observable Inputs (Level 2) |  |
Assets: |  |
Assets, fair value | 803,871 | 179,145
Liabilities: |  |
Liabilities, fair value | 2,859 | 3,971
Significant Other Observable Inputs (Level 2) | Current portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Significant Other Observable Inputs (Level 2) | Current contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Significant Other Observable Inputs (Level 2) | Long-term portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-Metabasis |  |
Liabilities: |  |
Liabilities, fair value | 2,859 | 3,971
Significant Other Observable Inputs (Level 2) | Short-term investments |  |
Assets: |  |
Assets, fair value | 803,871 | 179,145
Significant Other Observable Inputs (Level 2) | Note Receivable - Viking Therapeutics |  |
Assets: |  |
Assets, fair value | 0 | 0
Significant Other Observable Inputs (Level 2) | Investment in Warrants |  |
Assets: |  |
Assets, fair value | 0 | 0
Significant Unobservable Inputs (Level 3) |  |
Assets: |  |
Assets, fair value | 0 | 3,877
Liabilities: |  |
Liabilities, fair value | 8,941 | 9,990
Significant Unobservable Inputs (Level 3) | Current portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 3,618 | 4,618
Significant Unobservable Inputs (Level 3) | Current contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 36 | 86
Significant Unobservable Inputs (Level 3) | Long-term portion of contingent liabilities - Crystal |  |
Liabilities: |  |
Liabilities, fair value | 3,784 | 3,783
Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-CyDex |  |
Liabilities: |  |
Liabilities, fair value | 1,503 | 1,503
Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-Metabasis |  |
Liabilities: |  |
Liabilities, fair value | 0 | 0
Significant Unobservable Inputs (Level 3) | Short-term investments |  |
Assets: |  |
Assets, fair value | 0 | 0
Significant Unobservable Inputs (Level 3) | Note Receivable - Viking Therapeutics |  |
Assets: |  |
Assets, fair value | 0 | 3,877
Significant Unobservable Inputs (Level 3) | Investment in Warrants |  |
Assets: |  |
Assets, fair value | 0 | $ 0
Metabasis | Long-term contingent liabilities-Metabasis |  |
Liabilities: |  |
CVR payable to Metabasis | $ 3,800 |

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of obligations due all related parties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(3),(4)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_DueToRelatedPartiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=lgnd_CurrentPortionofLiabilityForContingentValueRightsCompanyCrystalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=lgnd_CurrentPortionofLiabilityForContingentValueRightsCompanyCydexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=lgnd_LongTermPortionofLiabilityForContingentValueRightsCompanyCrystalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=lgnd_LongTermPortionofLiabilityForContingentValueRightsCompanyCydexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=lgnd_LongTermPortionofLiabilityForContingentValueRightsCompanyMetabasisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_NotesReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |